Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 12Sezary Syndrome 8Mycosis Fungoides 8Melanoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5Immunoblastic Lymphadenopathy 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, Extranodal NK-T-Cell 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Neoplasm Metastasis 3Lymphoma, T-Cell 3Lymphoma, Large B-Cell, Diffuse 3Intraocular Lymphoma 3Hodgkin Disease 3Uveal Melanoma 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Stomach Neoplasms 1Recurrence 1

Interventions

Brentuximab Vedotin 4Bexarotene 2iratumumab 1Vitamin B 12 1Salvia hispanica seed extract 1Methotrexate 1Lenalidomide 1Folic Acid 1Cholecalciferol 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Primary Cutaneous Anaplastic Large Cell × Lenalidomide × Dermatologic × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡